Additionally, BRD4 inhibition could overcome cetuximab resistance in HNSCC highlighting that targeting EGFR using cetuximab would activate BRD4-dependent activation of other receptor tyrosine kinases including HER3, MET, and AXL [63]. Here, ERBB3 is linked to head and neck squamous cell carcinoma.